AGGIES LabBLOCKMINE
ThreatDerivedConfidence: ModerateSnapshot Nov 8, 2026 · assessed Nov 8, 2026

The most common stated reason among 1,113 current FDA shortage entries is "Not stated" (678)

Composition of shortage_reason among Current openFDA drug shortage records. Reasons are manufacturer-reported categories; many entries state no reason.

Why this matters

Stated reasons separate demand surges from manufacturing, quality, and discontinuation causes, which call for different resilience responses.

What the evidence says

  • Not stated: 678.
  • Other: 164.
  • Demand increase for the drug: 126.
  • Shortage of an active ingredient: 61.
  • Discontinuation of the manufacture of the drug: 46.
  • Delay in shipping of the drug: 21.
  • Requirements related to complying with good manufacturing practices: 14.
  • Regulatory delay: 2.
  • Routes of administration among Current entries: INTRAVENOUS 300, ORAL 228, INTRAMUSCULAR 175, Not stated 173.
Stated shortage reasons among Current entries.
Categorycount
Not stated678
Other164
Demand increase for the drug126
Shortage of an active ingredient61
Discontinuation of the manufacture of the drug46
Delay in shipping of the drug21
Stated shortage reasons among Current entries.

What remains uncertain

  • Reason fields are free-text categories chosen by reporters.
  • Package-level entries inflate counts for multi-presentation products.
  • Not a measure of clinical impact or national availability.

Scoring and methodology

SupplyFragility: Not scored (bm-scoring-0.1; factor completeness 20%)

Only documented_disruption has an input; lead time and substitutability are unavailable, so no composite is published.

FactorWeightValueDefinition
concentration0.25unknownObserved supplier or country concentration.
documented_disruption0.21Supported disruption incidents in the period.
lead_time_stress0.2unknownObserved lead-time stress (often unavailable).
limited_substitutability0.15unknownDocumented scarcity of substitutes.
geographic_exposure0.1unknownGeographic exposure at safe granularity.
digital_dependency_risk0.1unknownDeclared software component risk.

Timeline

  1. published

    Upstream last updated · Nov 6, 2026

  2. retrieved

    Retrieved · Nov 8, 2026

  3. assessed

    Assessed · Nov 8, 2026

Event, published, retrieved, and assessed times are stored separately and never conflated.

Explore the relationships

Related insights are linked only through shared sources or mapped topics. Open the evidence graph.

What to investigate next

  • Deduplicate to product level.
  • Join USGS and trade data for upstream input concentration once connectors are active.

Related insights

  • Supply Chain

    Derived

    Manufacturer concentration of current shortage postings: reporting-share HHI 593 over 940 entries

    An HHI computed over manufacturer shares of Current shortage postings. This is a reporting-share concentration, not a market-share HHI, and says nothing about who supplies the market.

    Current shortage postings by manufacturer (top 6).
    Categorycount
    Fresenius Kabi USA, LLC146
    Hospira, Inc.129
    Hikma Pharmaceuticals USA …76
    Baxter Healthcare Corporat…45
    Eugia US LLC42
    Current shortage postings by manufacturer (top 6).
    Confidence: Low1 source
    data Nov 8, 2026Read the evidence →
  • Healthcare

    Derived

    1,113 drug shortage entries are listed as Current by FDA

    Count of openFDA drug shortage records with status Current (upstream last updated 2026-11-06). Entries are product-level postings, not patient-level impact.

    Current shortage entries by therapeutic category (top 8).
    Categorycount
    Anesthesia359
    Pediatric227
    Psychiatry220
    Gastroenterology134
    Analgesia/Addiction126
    Current shortage entries by therapeutic category (top 8).
    Confidence: High1 source
    data Nov 8, 2026Read the evidence →

Export, cite, report

Found an error? Report a factual error or source correction. Last reviewed Nov 8, 2026.